Evaxion Biotech A/SNASDAQ:EVAX
- LAST PRICE4.1100
- TODAY'S CHANGE (%)0.0700 (1.7327%)
- Bid / Lots3.9300/ 2
- Ask / Lots4.1800/ 10
- Open / Previous Close4.1000 / 4.0400
- Day Range
- 52 Week Range
- Volume29,837
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EVAX |
|---|---|---|
| 09:32 ET | 3079 | 4.145 |
| 09:34 ET | 597 | 4.15 |
| 09:48 ET | 3880 | 4.1 |
| 10:03 ET | 5319 | 4.02 |
| 10:08 ET | 5765 | 4.035 |
| 10:12 ET | 623 | 4.1421 |
| 10:30 ET | 400 | 4.04 |
| 10:44 ET | 100 | 4.1272 |
| 11:02 ET | 1875 | 3.93 |
| 12:20 ET | 320 | 4.05 |
| 12:27 ET | 375 | 4.0301 |
| 01:53 ET | 388 | 4.08 |
| 03:09 ET | 1261 | 4.09 |
| 03:25 ET | 800 | 4.11 |
Yesterday
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01, from 8:00AM ET on Wednesday Apr 17, 2024 by Dow Jones
8:00AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 3, 2024
DJ Evaxion Biotech Price Target Maintained With a $14.00/Share by HC Wainwright & Co., from 6:49AM ET on Wednesday Apr 03, 2024 by Dow Jones
6:49AM ET on Wednesday Apr 03, 2024 by Dow Jones
Apr 2, 2024
DJ Evaxion Biotech Raised to Buy From Neutral by Ladenburg Thalmann, from 11:49AM ET on Tuesday Apr 02, 2024 by Dow Jones
11:49AM ET on Tuesday Apr 02, 2024 by Dow JonesEvaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection, from 7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 27, 2024
Evaxion Announces Business Update and Full Year 2023 Financial Results, from 7:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Evaxion Biotech A/S | 21.4M | -0.1x | --- |
Biora Therapeutics Inc | 21.4M | -0.1x | --- |
Cardio Diagnostics Holdings Inc | 22.0M | -1.4x | --- |
Context Therapeutics Inc | 22.2M | -0.9x | --- |
Bioxytran Inc | 20.5M | -3.9x | --- |
Vincerx Pharma Inc | 20.3M | -0.5x | --- |
Company Information
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Contact Information
- Headquarters
- Bredgade 34E, Copenhagen KCOPENHAGEN, Denmark 1260
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.4M |
|---|---|
Revenue (TTM) | $73.0K |
Shares Outstanding | 521.5K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-81.29 |
Book Value | $-1.25 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 293.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -30,406.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
